Scarica l'app Stockscreener
2.58
4.45%
0.11
Pre-mercato:
2.61
0.03
+1.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$2.47
Aprire:
$2.49
Volume 24 ore:
676.13K
Relative Volume:
0.07
Capitalizzazione di mercato:
$41.30M
Reddito:
$1.38M
Utile/perdita netta:
$-179.05M
Rapporto P/E:
-0.4202
EPS:
-6.14
Flusso di cassa netto:
$-155.03M
1 W Prestazione:
-11.03%
1M Prestazione:
-48.19%
6M Prestazione:
+12.66%
1 anno Prestazione:
+355.99%
Intervallo 1D:
$2.4701
$2.58
Intervallo di 1 settimana:
$2.47
$3.19
Portata 52W:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Industria
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Confronta BTAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
2.58 | 48.53M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BioXcel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Real time scanner hits for BioXcel Therapeutics Inc. explained2025 Volatility Report & Weekly High Return Opportunities - newser.com
Fundamentals Check: Is BioXcel Therapeutics Inc benefiting from interest rate changesWeekly Trade Report & Technical Analysis for Trade Confirmation - خودرو بانک
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Up 166.4% in August - MarketBeat
ETF Watch: How cyclical is BioXcel Therapeutics Incs revenue streamAnalyst Upgrade & Risk Controlled Stock Pick Alerts - خودرو بانک
Aug Reactions: How cyclical is BioXcel Therapeutics Incs revenue streamJuly 2025 Trends & Reliable Price Breakout Alerts - khodrobank.com
BioXcel Therapeutics regains Nasdaq compliance after MVLS issue By Investing.com - Investing.com South Africa
BioXcel Therapeutics regains compliance with Nasdaq market value of listed securities requirements - MarketScreener
BioXcel Therapeutics Regains Compliance With Nasdaq Market Value of Listed Securities Requirements - 富途牛牛
Volume spikes in BioXcel Therapeutics Inc. stock – what they meanMarket Weekly Review & AI Driven Price Predictions - newser.com
BioXcel Therapeutics (BTAI) Regains Nasdaq Compliance - GuruFocus
BioXcel Therapeutics regains Nasdaq compliance after MVLS issue - Investing.com
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements - The Manila Times
Biotech Firm BioXcel Therapeutics Secures Future on Nasdaq After Meeting $35M Market Value Threshold - Stock Titan
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Risk Check: How does BioXcel Therapeutics Inc correlate with Nasdaq2025 Price Action Summary & Free High Return Stock Watch Alerts - خودرو بانک
Institutional scanner results for BioXcel Therapeutics Inc.July 2025 Intraday Action & Daily Oversold Bounce Ideas - newser.com
Dip Buying: Is BioXcel Therapeutics Inc stock good for income investorsQuarterly Earnings Report & Verified Swing Trading Watchlists - خودرو بانک
Does BioXcel Therapeutics Inc have a competitive edgeMarket Trend Summary & AI Driven Price Forecasts - khodrobank.com
Profit Recap: Can BioXcel Therapeutics Inc. lead its sector in growthEarnings Risk Summary & Weekly Breakout Watchlists - خودرو بانک
How does Deswell Industries Inc compare to its peersMarket Performance Report & Low Drawdown Investment Ideas - خودرو بانک
Quarterly Trades: Is AutoNation Inc. affected by consumer sentimentJuly 2025 Levels & Consistent Growth Stock Picks - خودرو بانک
BTAI Secures $37.3M Through Equity Distribution and Warrant Exercises - GuruFocus
BTAI Completes Enrollment in Key Clinical Study - GuruFocus
BioXcel Therapeutics, Inc. Provides Clinical Trial Update - MarketScreener
Guidance Update: Does BioXcel Therapeutics Inc stock have upside surprise potentialWatch List & Technical Buy Zone Confirmations - خودرو بانک
Using economic indicators to assess BioXcel Therapeutics Inc. potentialGDP Growth & Reliable Intraday Trade Plans - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bioxcel Therapeutics (BTAI) and Alignment Healthcare (ALHC) - The Globe and Mail
Murchinson Ltd. Purchases Shares of 136,076 BioXcel Therapeutics, Inc. $BTAI - MarketBeat
BioXcel Therapeutics stock price target raised to $4 by Mizuho on positive trial data - Investing.com
BioXcel Therapeutics Reports Positive Phase 3 Trial Results - MSN
BioXcel reports positive efficacy data for at-home agitation treatment - Investing.com India
Transcript : BioXcel Therapeutics, Inc.Special Call - MarketScreener
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar PatientsBioXcel Therapeutics (NASDAQ:BTAI) - Benzinga
Bioxcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study - Menafn.com
BioXcel Therapeutics : SERENITY AT Home Topline September 10 - MarketScreener
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study - Stocktwits
BioXcel reports positive efficacy data for at-home agitation treatment By Investing.com - Investing.com Canada
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data From SERENITY At-Home Study - Nasdaq
BioXcel Therapeutics Announces Positive Phase 3 Trial Results for BXCL501 in Outpatient Treatment of Agitation Associated with Bipolar Disorders and Schizophrenia - Quiver Quantitative
BioXcel Therapeutics Reports Positive Topline Exploratory - GlobeNewswire
BioXcel Therapeutics, Inc. Reports Positive Topline Exploratory Efficacy Data from Serveity At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - MarketScreener
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data From SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated With Bipolar Disorders or Schizophrenia - 富途牛牛
BioXcel Therapeutics at H.C. Wainwright: Expanding IGALMI’s Reach By Investing.com - Investing.com Canada
BioXcel Therapeutics at H.C. Wainwright: Expanding IGALMI’s Reach - Investing.com
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Update - MarketBeat
BioXcel Therapeutics Receives Positive FDA Feedback - MSN
Can momentum traders help lift BioXcel Therapeutics Inc.Weekly Market Summary & Fast Entry and Exit Trade Plans - Newser
Technical signs of recovery in BioXcel Therapeutics Inc.Insider Selling & Daily Chart Pattern Signal Reports - Newser
Canaccord Genuity Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI) - The Globe and Mail
Is BioXcel Therapeutics Inc. part of any major indexJuly 2025 Macro Moves & Verified Swing Trading Watchlist - خودرو بانک
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):